Company news
Atara Biotherapeutics, Inc. news in 2026
Atara Biotherapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
November 10, 2026
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
October 14, 2026
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
September 30, 2026
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
August 12, 2026
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
May 12, 2026
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
April 1, 2026
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
March 16, 2026
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
March 3, 2026
Atara Biotherapeutics Provides a Business Update
February 23, 2026
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
January 12, 2026